Alzheimer's Disease And Dementia
Retinal microvascular abnormalities are identified in cognitively healthy individuals who have biomarkers positive for Alzheimer disease.
Positron emission tomographic imaging can directly measure synaptic loss with Alzheimer disease.
Currently, there are no approved treatments for behavioral symptoms in Alzheimer disease.
Investigators reviewed data from patients aged 45 to 64 years who were enrolled in the Atherosclerosis Risk in Communities Study and who attended additional visits for cognitive function evaluation and repeat cardiovascular risk factor assessment.
An international team of investigators assessed the ability of flutemetamol F 18-labeled PET and other biomarkers to predict risk of clinical progression from amnestic mild cognitive impairment to probable Alzheimer disease.
For an unselected memory clinic cohort, amyloid PET results are associated with changes in etiology, diagnostic confidence, and patient treatment.
While hundreds of published reports have made an argument for an association between Alzheimer disease and bacteria and viruses, the suggestion of a viral contribution to Alzheimer disease has not always been well received by the greater research community.
Phase 3 clinical trials for lanabecestat (Eli Lilly and AstraZeneca), an investigational Alzheimer disease treatment, are being discontinued for futility.
The risk of dementia is increased in 50-year-olds with blood pressure ≥130 mm Hg, which is below the current threshold for hypertension.
The lifetime risks of Alzheimer disease dementia vary considerably by age, gender, and the preclinical or clinical disease state.
There was an observable pattern with combined polyphenol intake and risk for dementia in the study cohort.
Janssen announced that the Company will no longer continue studying atabecestat, an investigational treatment for asymptomatic patients at risk for developing Alzheimer disease.
These results suggest that antipsychotic exposure has no impact on relative mortality.
Multimarker inflammatory biosignatures are expected to facilitate diagnosis and predict treatment outcomes for various central nervous system disorders, particularly Alzheimer disease and major depressive disorder.
Methylphenidate demonstrated an improvement in apathy vs placebo when measured by the apathy evaluation scale, in addition, methylphenidate showed possible improvement in cognition.
Use of anticholinergic drugs may be tied to a future diagnosis of dementia.
Additional examination of these relationships is warranted to help clarify the complex biologic and psychosocial interactions among Alzheimer disease, malignant melanoma, and nonmelanoma skin cancer.
Results showed that after 18-months, there was no significant statistical difference in cognitive or functional outcomes between those patients taking azeliragon and the placebo group.
About half of adults surveyed expect a man with mild Alzheimer dementia to be discriminated against.
Findings show lower post-surgical mortality among patients with Alzheimer's disease.
Molecular markers can identify changes associated with the disease before clinical onset for young adults with autosomal dominant AD.
Merck announced the discontinuation of the Phase 3 APECS study for the treatment of AD.
Positive beliefs on age may protect against dementia.
The use of DBS in patients with Alzheimer disease is well tolerated and associated with less decline on the CDR-SB.
A study was conducted to assess potential beneficial effects of a lifestyle intervention program on cognition in carriers of the APOE ε4 allele.
Solanezumab does not alter cognitive decline in patients with mild Alzheimer disease.
Brain amyloidosis is associated with certain Alzheimer disease risk variants.
Because of dementia's prolonged disease course, advance care decisions and planning are often overlooked until it is too late.
For patients with mild-to-moderate Alzheimer disease, the use of idalopirdine does not improve cognition.
There is an increased risk of dementia for patients with rheumatic diseases.
Neurology Advisor Articles
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- Gender and Multiple Sclerosis: How It Influences Prognosis and Future Treatment
- Drug Prices Increase More Than Expected After Shortages
- Potentially Inappropriate Opioid Prescribing Tied to Overdose
- Loss of Function Variants in LRKK1 and LRKK2 Not Linked to Parkinson Disease
- Scribes Improve Physician Workflow, Patient Interaction